Brind.
  1. Syndax Pharmaceuticals has FDA-approved therapies in its pipeline and uses LinkedIn for company communication.

FDA granted Priority Review for Syndax's sNDA on June 25, 2025.

2 reports, 0 independent Updated Jun 25
Gone quiet
Reports
2
Developments
2
Repetition
0%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

SpeculativeNo independent reporting found

FDA granted Priority Review for Syndax's sNDA on June 25, 2025.

Who's involved

What this event is mainly about
FDASyndax Pharmaceuticals

How it developed

Newest first. Tap a step to see who reported it.
  1. FDA granted Priority Review for Syndax's sNDA.
  2. FDA granted priority review for Syndax's Revuforj application on June 25, 2025.

Keep exploring

Part of

Syndax Pharmaceuticals has FDA-approved therapies in its pipeline and uses LinkedIn for company communication. All 1 developments

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • Unknown outlet
  • Unknown outlet